Hyperlipidemia and Statins Use for the Risk of New Diagnosed Sarcopenia in Patients with Chronic Kidney: A Population-Based Study

Min-Hua Lin; She-Yu Chiu; Pei-Hsuan Chang; Yu-Liang Lai; Pau-Chung Chen; Wen-Chao Ho

doi:10.3390/ijerph17051494

Hyperlipidemia and Statins Use for the Risk of New Diagnosed Sarcopenia in Patients with Chronic Kidney: A Population-Based Study

Int J Environ Res Public Health. 2020 Feb 26;17(5):1494. doi: 10.3390/ijerph17051494.

Authors

Min-Hua Lin^{1

2}, She-Yu Chiu¹, Pei-Hsuan Chang^{3

4}, Yu-Liang Lai^{5

6}, Pau-Chung Chen⁷, Wen-Chao Ho⁴

Affiliations

¹ Department of Nutrition, China Medical University, Taichung 40402, Taiwan.
² Department of Dietetics, Yunlin Christian Hospital, Yunlin 64866, Taiwan.
³ Department of Clinical Nutrition, China Medical University Hospital, Taichung 40402, Taiwan.
⁴ Department of Public Health, China Medical University, Taichung 40402, Taiwan.
⁵ Department of Physical Therapy Medicine and rehabilitation, China Medical University, Hsinchu 302, Taiwan.
⁶ Department of Physical Therapy and School of Medicine, China Medical University, Taichung 40402, Taiwan.
⁷ Department of Public Health, National Taiwan University, Taipei 10617, Taiwan.

Abstract

Background: Previous research found that statins, in addition to its efficiency in treating hyperlipidemia, may also incur adverse drug reactions, which mainly include myopathies and abnormalities in liver function. Aim: This study aims to assess the risk for newly onset sarcopenia among patients with chronic kidney disease using statins. Material and Method: In a nationwide retrospective population-based cohort study, 75,637 clinically confirmed cases of chronic kidney disease between 1997 and 2011were selected from the National Health Insurance Research Database of Taiwan. The selection of the chronic kidney disease cohort included a discharge diagnosis with chronic kidney disease or more than 3 outpatient visits with the diagnosis of chronic kidney disease found within 1 year. After consideration of patient exclusions, we finally got a total number of 67,001 cases of chronic kidney disease in the study. The Cox proportional hazards model was used to perform preliminary analysis on the effect of statins usage on the occurrence of newly diagnosed sarcopenia; the Cox proportional hazards model with time-dependent covariates was conducted to take into consideration the individual temporal differences in medication usage, and calculated the hazard ratio (HR) and 95% confidence interval after controlling for gender, age, income, and urbanization. Results: Our main findings indicated that patients with chronic kidney disease who use statins seem to effectively prevent patients from occurrences of sarcopenia, high dosage of statins seem to show more significant protective effects, and the results are similar over long-term follow-up. In addition, the risk for newly diagnosed sarcopenia among patients with lipophilic statins treatment was lower than that among patients with hydrophilic statins treatment. Conclusion: It seems that patients with chronic kidney disease could receive statin treatment to reduce the occurrence of newly diagnosed sarcopenia. Additionally, a higher dosage of statins could reduce the incidence of newly diagnosed sarcopenia in patients with chronic kidney disease.

Keywords: chronic kidney disease; sarcopenia; statins.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Aged
Cohort Studies
Female
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / adverse effects
Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
Hyperlipidemias* / complications
Hyperlipidemias* / drug therapy
Incidence
Male
Middle Aged
Proportional Hazards Models
Renal Insufficiency, Chronic* / complications
Retrospective Studies
Sarcopenia* / chemically induced
Sarcopenia* / complications
Taiwan

Substances

Hydroxymethylglutaryl-CoA Reductase Inhibitors